Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
Same journal

Isolation of Compounds.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
Same journal

Detection of Phenolic and Flavonoid Compounds Using High Performance Thin Layer Chromatography (HPTLC).

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
Same journal

Protein Bioavailability in Animal Model.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
Same journal

Induction of Apoptosis.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
Same journal

Determination of Cytotoxicity.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2016
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K

Anti-tumour Activity

    Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques
    |March 5, 2016
    PubMed
    Summary
    This summary is machine-generated.

    This study details protocols for evaluating antitumor activity using two common experimental tumor models: Dalton's ascites lymphoma (DAL) and Ehrlich ascites carcinoma (EAC). These models are crucial for cancer research and drug development.

    More Related Videos

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    12.9K
    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
    19:44

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

    Published on: May 30, 2012

    19.3K

    Related Experiment Videos

    Last Updated: Mar 24, 2026

    Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
    09:20

    Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

    Published on: June 26, 2018

    8.8K
    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    12.9K
    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
    19:44

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

    Published on: May 30, 2012

    19.3K

    Area of Science:

    • Oncology
    • Experimental Pathology
    • Cancer Research

    Background:

    • Dalton's ascites lymphoma (DAL) and Ehrlich ascites carcinoma (EAC) are widely used experimental tumor models.
    • Ehrlich ascites carcinoma originated from spontaneous mouse breast cancer and was adapted for experimental use.
    • The liquid ascites form of EAC was established in 1932, facilitating its use in research.

    Purpose of the Study:

    • To establish a standardized protocol for determining antitumor activity.
    • To utilize two common experimental tumor models, EAC and DAL, for evaluating therapeutic efficacy.
    • To provide a framework for preclinical cancer research using established ascites tumor models.

    Main Methods:

    • Selection of two common experimental tumor cells: Ehrlich ascites carcinoma (EAC) and Dalton's ascites lymphoma (DAL).
    • Development of a protocol to assess the antitumor effects against these selected tumor models.
    • Utilizing established methods for tumor cell propagation and administration in experimental settings.

    Main Results:

    • The study focuses on establishing a methodology rather than presenting specific experimental results.
    • The protocol aims to provide a reproducible means to evaluate antitumor responses.
    • The chosen models (EAC and DAL) are suitable for assessing a wide range of potential antitumor agents.

    Conclusions:

    • Standardized protocols are essential for reliable evaluation of antitumor activity in experimental models.
    • EAC and DAL represent valuable tools for preclinical cancer research and drug screening.
    • This work provides a foundational protocol for future studies investigating novel cancer therapies.